Semaglutide starting material Boc-His(Trt)-Aib-OH
TDS 1 Inquiries
2061897-68-3
Pharmaceutical Grade
95%
Shanghai or Beijing
HANDOM CHEM
1g/bottle, 3g/bottle, 5g/bottle, 10g/bottle
2024-02-04
Semaglutide,Tirzepatide,HCG,Retatrutide,Cagrilintide,Medetomidine
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificatesBasic Info
-
Product Name:
Boc-His(Trt)-Aib-OH
Other Name:(Tert-Butoxy)Carbonyl L-His(Trt)-Aib-OH;BOC-L-HIS(TRT)-AIB-OH;2-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]propanamido]-2-methylpropanoic acid;(S)-2-(2-((tert-Butoxycarbonyl)amino)-3-(1-trityl-1H-imidazol-4-yl)propanamido)-2-methylpropanoic acid;Boc-His(Trt)-Aib-OH;BOC-L-HIS(TRT)-AIB-OH，Semaglutide sidechain;(S)-2-[2-(Boc-amino)-3-(1-trityl-4-imidazolyl)propanamido]-2-methylpropanoic Acid;Semaglutide Chain Chian
CAS No.:2061897-68-3
Molecular Formula:C34H38N4O5
InChIKeys:POZCMPSLNOUKQN-NPFCIKOQNA-N
Molecular Weight:582.7
Exact Mass:582.28422033
Color/Form:White to Off-White
Categories:
Characteristics-
Density:
1.17±0.1 g/cm3(Predicted)
Boiling Point:789.3±60.0 °C(Predicted)
PKA:3.43±0.10(Predicted)
Critical Temperature & Pressure:Store at room temperature
Research-
Class:
GLP-1R agonist
Status:FDA-approved (Ozempic / Wegovy / Rybelsus)
Mechanism:Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.
Activity note:Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).
Source:Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI
Clinical Development:FDA:Ozempic, Wegovy, Rybelsus (approved 2017-12-05)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
NEJM: Wilding et al. (2021) — STEP-1; NEJM: Marso et al. (2016) — SUSTAIN-6; J Med Chem: Lau et al. (2015) — Discovery of Semaglutide; FDA: Ozempic (NDA 209637)
Disclaimer:Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Semaglutide,Tirzepatide,HCG,Retatrutide,Cagrilintide,Medetomidine
-
Location:
RM702, Building 21, Liuhe Road, Ganjingzi Dist, Dalian, Liaoning, China
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
15
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2020
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted 
India
Boc-His(Trt)-Aib-OH
10 KG May 7, 2025 Post an enquiry for this product
